Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | FBP1 | P09467 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10624853 | 0.83 | GABRA5 (0.46) | GABRA5GABRB2HSD17B10NOS1RAB9A | |
| SCHEMBL7860486 | 0.79 | PNP (0.43) | GABRA5GABRB2HSD17B10NOS1RAB9A | |
| SCHEMBL10624819 | 0.78 | GABRA5 (0.44) | GABRA5GABRB2HSD17B10NOS1RAB9A | |
| SCHEMBL10624761 | 0.77 | FDPS (0.44) | GABRA5GABRB2HSD17B10NOS1RAB9A | |
| SCHEMBL4295158 | 0.72 | SLC6A3 (0.35) | PNPSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2919667 | 0.69 | GABRA5 (0.56) | GABRA5GABRB2HSD17B10NOS1RAB9A | |
| SCHEMBL2211332 | 0.69 | — | — | |
| SCHEMBL18555264 | 0.68 | GABRA5 (0.48) | GABRA5GABRB2HSD17B10NOS1RAB9A | |
| SCHEMBL2655261 | 0.67 | GABRA5 (0.68) | GABRA5GABRB2HSD17B10NOS1RAB9A | |
| SCHEMBL307817 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1112275-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000014095-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |